Biotech Startups

āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers. Its lead product is the antibody andecaliximab.

1 investor

Ashish Life Science Pvt Limited manufactures veterinary and animal health pharmaceutical products, serving customers worldwide. Part of the Ashish Group of Industries, it operates a GMP-compliant manufacturing facility for its animal health product range.

1 investor

Ashlins Pharmaceuticals develops therapeutics for rare and underserved diseases, focusing on programs with scientific validation and accelerated regulatory pathways to deliver treatments where patient options are limited.

1 investor

1 investor

Asieris Pharmaceuticals develops and commercializes drugs and diagnostic devices focused on cancer and other therapeutic areas, including treatments for advanced solid tumors and urological conditions. Its pipeline spans small-molecule drugs, antibody-drug conjugates, and imaging devices such as cystoscopes.

1 investor

Asima Health is developing a non-invasive, multi-cancer blood test that uses a pan-genomic platform to detect multiple cancers from a single blood draw. The portable technology is intended for use through local diagnostic labs as part of routine blood work to identify people at risk who may need further screening.

1 investor

AsimicA is a B2B strain engineering company that develops Microbial Stem Cell Technology (MiST) to repopulate microbial biofactories with young, productive cells during fermentation, reducing downtime and increasing yields. Its technology serves larger biotech fermentation companies producing industrial quantities of drugs, biofuels, materials, and food ingredients.

1 investor

Asius Technologies develops high-end professional in-ear monitors and earbuds designed to improve sound quality while reducing ear damage from air pressure. Its products target sound engineers, musicians, military personnel, and audiophiles who use earbuds for extended periods.

1 investor

AskAt is a pharmaceutical company focused on developing new drugs with novel mechanisms for conditions that lack effective treatments, such as cancer, dementia, and autoimmune diseases. It aims to bring these therapies to patients worldwide.

1 investor

Aspen Biosciences provides consulting, advisory, and research resources focused on drug discovery and biopharmaceutical R&D, serving pharmaceutical and biotech companies navigating program management, digital transformation, and emerging technologies like AI.

1 investor

AspiAir is a clinical-stage biotech company developing LASAG Inhale, an inhaled non-opioid treatment for pain and migraine attacks using acetylsalicylic acid. The company serves patients in the EU who lack access to adequate migraine medications and aims to provide a safe, mobile alternative to current therapies.

1 investor

Aspira Women's Health develops and commercializes blood-based diagnostic tests using artificial intelligence and multiple biomarkers to help assess the risk of ovarian cancer and other gynecologic diseases in women. The company operates a CLIA-certified laboratory in Texas and distributes its tests—including Ova1Plus and OvaWatch—through a direct sales force and channel partnerships with laboratory providers.

1 investor

AviadoBio is a biotech company focused on frontotemporal dementia (FTD), a form of early-onset dementia. The company engages with patients, families, and caregivers affected by FTD to develop treatment solutions.

1 investor

Aspire Pharma is a UK-based pharmaceutical company, founded in 2009, that develops and markets niche generic and branded medicines across therapy areas including urology, CNS, respiratory, ophthalmology and dermatology. It is expanding across Europe, with entities in Ireland and Germany, and grows through acquisitions and licensing deals.

1 investor

iAssist is a specialty therapy initiation platform that helps patients access prescribed therapies by reducing administrative delays and improving communication between patients, healthcare providers, and manufacturers. The platform serves nurses, healthcare practices, and oncology drug manufacturers in the specialty pharmaceutical sector.

1 investor

AssureDrop develops droplet microfluidics-based screening technology that works within standard multiwell plates for pipette-free, high-throughput screening of 3D cell models such as spheroids. It targets biotechnology and cancer research applications including drug discovery, personalized medicine, and genetic analysis using limited biological samples like patient biopsies and stem cells.

1 investor

Assyro is an AI medical writing software platform that automates the drafting of clinical study reports, protocols, and patient narratives from source data. It serves pharmaceutical and clinical research organizations by reducing the time and manual effort required for medical writing, quality control, and regulatory submissions.

1 investor

Asta Biotx develops targeted radiotherapy for cancer by combining the alpha-emitting radioisotope 211-Astatine with its proprietary Radiobody targeting molecules based on multivalent single-domain antibodies. The approach aims to deliver radiation precisely to tumor cells while sparing healthy tissue.

1 investor

Asterix Foods produces functional proteins from sugar and water using plant-cell-based, modular single-use manufacturing instead of animals, starting with lactoferrin for applications such as infant nutrition and iron support. It develops an animal-free protein production platform aimed at making high-value bioactive proteins accessible to food and nutrition markets.

1 investor

Aston Particle Technologies develops the iDPC (dry particle coater) technology for pharmaceutical and biotechnology companies to support drug formulation and development. The company serves the pharmaceutical and biotechnology sectors with forward-thinking scientific solutions.

1 investor

Astratus develops a semi-automated laboratory platform using a microcapillary "dip and test" cassette and instrument reader for rapid antimicrobial susceptibility testing (AST), delivering results in under 6 hours directly from urine or bacterial isolates. It serves human, veterinary, and research markets, supporting clinical laboratories with antimicrobial stewardship and researchers developing new antimicrobials and therapies.

1 investor

Atanis Biotech develops FAST-PASE®, a blood-based allergy diagnostic test that measures how a patient's blood activates mast cells in response to specific food and other allergens, avoiding skin pricks and food challenges. The test targets common food allergens (egg, milk, peanut, cashew) and Alpha-gal red meat allergy, and is currently in development for use by patients and healthcare providers.

1 investor

Atelerix Life Sciences develops novel respiratory therapies for drug-induced respiratory depression, respiratory disease exacerbations, and bio-defense against respiratory threats. The company is advancing pre-clinical and clinical-stage drug candidates, with ATLX-0199 as its lead compound designed to stimulate respiratory drive while preserving pain relief and sedation.

1 investor

ATEM Capital is a venture investor focused on life sciences, backing early- and growth-stage biopharma and healthtech companies across the US and Western Europe. Its portfolio spans biotech therapeutics, AI drug discovery, digital therapeutics, and healthcare robotics.

1 investor